Receipts for the three-month period ended Dec. 31 surged to $4.7 million from $2.6 million one year ago.
R&D spending, meantime, also increased in the fourth quarter to $6 million from $4.3 million in the year-ago period.
Net loss widened to $6.5 million, or $.28 per share, from $5.4 million, or $.24 per share, year over year, Genaissance said.
The company said it had around $16.8 million in cash, cash equivalents, and marketable securities as of Dec. 31.
Click here for more information.